SCOT研究:结直肠癌辅助奥沙利铂联合氟尿嘧啶3个月对比6个月的非劣效性III期试验
SCOT研究为国际随机III期非劣效性试验,纳入6088例高危II期和III期结直肠癌患者,比较3个月与6个月辅助奥沙利铂联合氟尿嘧啶方案的疗效。3个月组周围神经毒性显著更低,生活质量更优。
要点
- 3个月组2级及以上周围神经毒性发生率为25%,显著低于6个月组的58%。
- 缩短疗程可减少毒性并改善生活质量,可能成为新的标准治疗选择。
核心结论
- 在高危II期和III期结直肠癌患者中,3个月辅助奥沙利铂联合氟尿嘧啶化疗非劣效于6个月方案。
- 3个月方案与更低的毒性和更好的生活质量相关,可能代表新的标准治疗。
研究设计与样本
- SCOT研究为国际、随机、III期、非劣效性试验,在244个中心开展。
- 共随机分配6088例患者,3个月组和6个月组各3044例,意向性分析人群分别为3035例和3030例。
- 患者为18岁及以上高危II期和III期结直肠癌,随机前选择CAPOX或FOLFOX方案。
主要发现
- 中位分析截止时共发生1482例无病生存事件,3个月组740例,6个月组742例。
- 2级及以上周围神经毒性在6个月组为58%(237/409例),3个月组为25%(103/420例),且持续时间长并影响生活质量。
- 严重不良事件共1098例报告(3个月组492例,6个月组606例),治疗相关死亡32例(每组各16例)。
关键数值与推荐
- 2级及以上周围神经毒性发生率3个月组25%(103/420),6个月组58%(237/409)。
临床怎么用
- 对于高危II期和III期结直肠癌患者,可考虑将辅助奥沙利铂联合氟尿嘧啶化疗缩短至3个月。
- 缩短疗程有助于降低周围神经毒性并改善生活质量,尤其适用于CAPOX方案患者。
- 临床决策时应结合患者复发风险、方案选择及耐受性进行个体化评估。
局限性
- 研究因事件数少于预期而统计效能不足。
- 安全性分析仅基于部分有安全性数据的患者子集。
- 随访仍在进行中,长期生存数据尚未成熟。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: 6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether 3 months of oxaliplatin-containing chemotherapy would be non-inferior to the usual 6 months of treatment. METHODS: The SCOT study was an international, randomised, phase 3, non-inferiority trial done at 244 centres. Patients aged 18 years or older with high-risk stage II and stage III colorectal cancer underwent central randomisation with minimisation for centre, choice of regimen, sex, disease site, N stage, T stage, and the starting dose of capecitabine. Patients were assigned (1:1) to receive 3 months or 6 months of adjuvant oxaliplatin-containing chemotherapy. The chemotherapy regimens could consist of CAPOX (capecitabine and oxaliplatin) or FOLFOX (bolus and infused fluorouracil with oxaliplatin). The regimen was selected before randomisation in accordance with choices of the patient and treating physician. The primary study endpoint was disease-free survival and the non-inferiority margin was a hazard ratio of 1·13. The primary analysis was done in the intention-to-treat population and safety was assessed in patients who started study treatment. This trial is registered with ISRCTN, number ISRCTN59757862, and follow-up is continuing. FINDINGS: 6088 patients underwent randomisation between March 27, 2008, and Nov 29, 2013. The intended treatment was FOLFOX in 1981 patients and CAPOX in 4107 patients. 3044 patients were assigned to 3 month group and 3044 were assigned to 6 month group. Nine patients in the 3 month group and 14 patients in the 6 month group did not consent for their data to be used, leaving 3035 patients in the 3 month group and 3030 patients in the 6 month group for the intention-to-treat analyses. At the cutoff date for analysis, there had been 1482 disease-free survival events, with 740 in the 3 month group and 742 in the 6 month group. 3 year disease-free survival was 76·7% (95% CI 75·1-78·2) for the 3 month group and 77·1% (75·6-78·6) for the 6 month group, giving a hazard ratio of 1·006 (0·909-1·114, test for non-inferiority p=0·012), significantly below the non-inferiority margin. Peripheral neuropathy of grade 2 or worse was more common in the 6 month group (237 [58%] of 409 patients for the subset with safety data) than in the 3 month group (103 [25%] of 420) and was long-lasting and associated with worse quality of life. 1098 serious adverse events were reported (492 reports in the 3 month group and 606 reports in the 6 month group) and 32 treatment-related deaths occurred (16 in each group). INTERPRETATION: In the whole study population, 3 months of oxaliplatin-containing adjuvant chemotherapy was non-inferior to 6 months of the same therapy for patients with high-risk stage II and stage III colorectal cancer and was associated with reduced toxicity and improved quality of life. Despite the fact the study was underpowered, these data suggest that a shorter duration leads to similar survival outcomes with better quality of life and thus might represent a new standard of care. FUNDING: Medical Research Council, Swedish Cancer Society, NETSCC, and Cancer Research UK.
引用
- Iveson TJ, Kerr RS, Saunders MP, et al. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2018. PMID: 29611518. doi:10.1016/S1470-2045(18)30093-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。